
    
      The Investigators are undertaking a parallel, multicentre, randomised open-label trial of
      newly diagnosed AML (not APL) patients in China. Participants are randomised selected to
      receive the regimen of Ara-C, aclarubicin and PEG-G-CSF , or the regimen of Ara-C,
      aclarubicin and G-CSF (CAG ).Platelet count, bleeding and other symptoms are evaluated before
      and after treatment. Adverse events are also recorded throughout the study.
    
  